BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Csizmadia V, Hales P, Tsu C, Ma J, Chen J, Shah P, Fleming P, Senn JJ, Kadambi VJ, Dick L, Wolenski FS. Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi. Toxicol Res (Camb) 2016;5:1619-28. [PMID: 30090462 DOI: 10.1039/c6tx00220j] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Kingsley LJ, He X, McNeill M, Nelson J, Nikulin V, Ma Z, Lu W, Zhou VW, Manuia M, Kreusch A, Gao MY, Witmer D, Vaillancourt MT, Lu M, Greenblatt S, Lee C, Vashisht A, Bender S, Spraggon G, Michellys PY, Jia Y, Haling JR, Lelais G. Structure-Based Design of Selective LONP1 Inhibitors for Probing In Vitro Biology. J Med Chem 2021;64:4857-69. [PMID: 33821636 DOI: 10.1021/acs.jmedchem.0c02152] [Reference Citation Analysis]
2 Maneix L, Sweeney MA, Lee S, Iakova P, Moree SE, Sahin E, Lulla P, Yellapragada SV, Tsai FTF, Catic A. The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers (Basel) 2021;13:843. [PMID: 33671345 DOI: 10.3390/cancers13040843] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Thibaudeau TA, Smith DM. A Practical Review of Proteasome Pharmacology. Pharmacol Rev 2019;71:170-97. [PMID: 30867233 DOI: 10.1124/pr.117.015370] [Cited by in Crossref: 98] [Cited by in F6Publishing: 84] [Article Influence: 32.7] [Reference Citation Analysis]